Xorafia 200 mg apvalkotās tabletes Letland - lettisk - Zāļu valsts aģentūra

xorafia 200 mg apvalkotās tabletes

lv system service sia, latvia - sorafenibs - apvalkotā tablete - 200 mg

Ximluci Den Europæiske Union - lettisk - EMA (European Medicines Agency)

ximluci

stada arzneimittel ag - ranibizumab - wet macular degeneration; macular edema; diabetic retinopathy; diabetes complications - oftalmoloģiskie līdzekļi - ximluci is indicated in adults for:the treatment of neovascular (wet) age-related macular degeneration (amd)the treatment of visual impairment due to diabetic macular oedema (dme)the treatment of proliferative diabetic retinopathy (pdr)the treatment of visual impairment due to macular oedema secondary to retinal vein occlusion (branch rvo or central rvo)the treatment of visual impairment due to choroidal neovascularisation (cnv).

Sorafenib Accord Den Europæiske Union - lettisk - EMA (European Medicines Agency)

sorafenib accord

accord healthcare s.l.u. - sorafenib tosilate - carcinoma, hepatocellular; carcinoma, renal cell - antineoplastiski līdzekļi - hepatocellular carcinomasorafenib accord is indicated for the treatment of hepatocellular carcinoma (see section 5. renal cell carcinomasorafenib accord is indicated for the treatment of patients with advanced renal cell carcinoma who have failed prior interferon-alpha or interleukin-2 based therapy or are considered unsuitable for such therapy.

Ranivisio Den Europæiske Union - lettisk - EMA (European Medicines Agency)

ranivisio

midas pharma gmbh - ranibizumab - wet macular degeneration; macular edema; diabetic retinopathy; diabetes complications - oftalmoloģiskie līdzekļi - ranivisio is indicated in adults for:• the treatment of neovascular (wet) age-related macular degeneration (amd)• the treatment of visual impairment due to diabetic macular oedema (dme)• the treatment of proliferative diabetic retinopathy (pdr)• the treatment of visual impairment due to macular oedema secondary to retinal vein occlusion (branch rvo or central rvo)• the treatment of visual impairment due to choroidal neovascularisation (cnv).

Suphrex 12,5 mg cietās kapsulas Letland - lettisk - Zāļu valsts aģentūra

suphrex 12,5 mg cietās kapsulas

lv system service, latvia - sunitinibs - kapsula, cietā - 12,5 mg

Suphrex 50 mg cietās kapsulas Letland - lettisk - Zāļu valsts aģentūra

suphrex 50 mg cietās kapsulas

lv system service, latvia - sunitinibs - kapsula, cietā - 50 mg

Suprane 100% inhalācijas tvaiki, šķidrums Letland - lettisk - Zāļu valsts aģentūra

suprane 100% inhalācijas tvaiki, šķidrums

baxter latvia, sia, latvia - desflurāns - inhalācijas tvaiki, šķidrums - 100%

Sunitinib Be Pharma 12,5 mg cietās kapsulas Letland - lettisk - Zāļu valsts aģentūra

sunitinib be pharma 12,5 mg cietās kapsulas

be pharma d.o.o., slovenia - sunitinibs - kapsula, cietā - 12,5 mg

Sunitinib Be Pharma 25 mg cietās kapsulas Letland - lettisk - Zāļu valsts aģentūra

sunitinib be pharma 25 mg cietās kapsulas

be pharma d.o.o., slovenia - sunitinibs - kapsula, cietā - 25 mg

Sunitinib Be Pharma 37,5 mg cietās kapsulas Letland - lettisk - Zāļu valsts aģentūra

sunitinib be pharma 37,5 mg cietās kapsulas

be pharma d.o.o., slovenia - sunitinibs - kapsula, cietā - 37,5 mg